Suppliers / Ningxia Qiyuan Pharmaceutical

Ningxia Qiyuan Pharmaceutical

China Updated 9 July 2026

Ningxia Qiyuan Pharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files and 5 valid CEPs across a filed portfolio of 4 molecules. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 28 June 2019 as VAI.

3
active US DMFs
5
valid CEPs
4
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 28 June 2019 VAI US FDA
  • 28 April 2016 VAI US FDA
  • 12 September 2014 VAI US FDA
  • 28 September 2012 VAI US FDA
  • 6 May 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Yingchuan, China Not on file
China, China 3004341367
Yinchuan City, China Not on file
Yinchuan, China Not on file

What they file, and where

Molecule Regulators Docs
Erythromycin EDQM, US FDA 4
Tetracycline EDQM, US FDA 2
Ascorbic Acid EDQM 1
Azithromycin EDQM 1

Also appears on these molecule pages

Azithromycin API Erythromycin API Tetracycline API

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Ningxia Qiyuan Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 June 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates